These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy. Nørgård BM Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578 [TBL] [Abstract][Full Text] [Related]
3. Anti-TNF therapy in inflammatory bowel diseases: a huge review. Peyrin-Biroulet L Minerva Gastroenterol Dietol; 2010 Jun; 56(2):233-43. PubMed ID: 20485259 [TBL] [Abstract][Full Text] [Related]
5. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? D'Haens GR; Panaccione R; Higgins PD; Vermeire S; Gassull M; Chowers Y; Hanauer SB; Herfarth H; Hommes DW; Kamm M; Löfberg R; Quary A; Sands B; Sood A; Watermeyer G; Lashner B; Lémann M; Plevy S; Reinisch W; Schreiber S; Siegel C; Targan S; Watanabe M; Feagan B; Sandborn WJ; Colombel JF; Travis S Am J Gastroenterol; 2011 Feb; 106(2):199-212; quiz 213. PubMed ID: 21045814 [TBL] [Abstract][Full Text] [Related]
6. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement. Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279 [TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor-α monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology. Lee TW; Fedorak RN Gastroenterol Clin North Am; 2010 Sep; 39(3):543-57. PubMed ID: 20951917 [TBL] [Abstract][Full Text] [Related]
8. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Hanauer SB Gut; 2007 Sep; 56(9):1181-3. PubMed ID: 17698862 [TBL] [Abstract][Full Text] [Related]
9. [Compared azathioprine efficacy in ulcerative colitis and in Crohn's disease]. Kull E; Beau P Gastroenterol Clin Biol; 2002 Apr; 26(4):367-71. PubMed ID: 12070412 [TBL] [Abstract][Full Text] [Related]
10. [Treatment of ulcerative colitis and Crohn's disease with monoclonal antibody]. Asakura H Nihon Rinsho; 2002 Mar; 60(3):531-8. PubMed ID: 11904969 [TBL] [Abstract][Full Text] [Related]
12. Addition of thiopurines can recapture response in patients with Crohn's disease who have lost response to anti-tumor necrosis factor monotherapy. Ong DE; Kamm MA; Hartono JL; Lust M J Gastroenterol Hepatol; 2013 Oct; 28(10):1595-9. PubMed ID: 23662928 [TBL] [Abstract][Full Text] [Related]
13. Immunosuppressive agents in the treatment of Crohn's disease and ulcerative colitis. Hibi T; Iwao Y; Yajima T; Inoue N; Ueno Y; Takaishi H; Watanabe M; Ishii H J Gastroenterol; 1995 Nov; 30 Suppl 8():121-3. PubMed ID: 8563872 [TBL] [Abstract][Full Text] [Related]
14. Decreasing trends in hospitalizations during anti-TNF therapy are associated with time to anti-TNF therapy: Results from two referral centres. Mandel MD; Balint A; Golovics PA; Vegh Z; Mohas A; Szilagyi B; Szabo A; Kurti Z; Kiss LS; Lovasz BD; Gecse KB; Farkas K; Molnar T; Lakatos PL Dig Liver Dis; 2014 Nov; 46(11):985-90. PubMed ID: 25156871 [TBL] [Abstract][Full Text] [Related]
15. [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease]. Rozpondek P; Zwolińska-Wcisło M; Przybylska M; Mach T Przegl Lek; 2011; 68(9):602-5. PubMed ID: 22335009 [TBL] [Abstract][Full Text] [Related]
16. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study. Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984 [TBL] [Abstract][Full Text] [Related]